Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (207)	9/6/2000 10:27:55 PM
From: Jim Oravetz	Read Replies (1) of 370

MELASYN: Vitiligo Solutions Inc. (a San-Mar subsidiary) began marketing MELASYN Æ-based products in February 1999. The products are designed to treat vitiligo, a non-life threatening, but emotionally devastating skin disease that results in blotchy, white spots on the skin. VION receives royalties on all sales (8%). I looked briefly at the latest 10K. No much about this drug or the profits from it. I think it brought in less than $10K is revenue. The Future of TAPET: While the preclinical results with VPN20009 appear very promising, we feel the real power of TAPET is the ability to over express proteins of interest within the tumor. By "arming" the bacteria with the ability to express the appropriate protein, additional anticancer efficacy should be observed. For example, the bacteria could be engineered to express a protein known as a prodrug converting enzyme at the tumor site. Such an enzyme present within the tumor could modify a relatively inert molecule and turn it into an active chemotherapeutic agent. A specific example is the use of cytosine deaminase expression in the tumor and the administration of 5-Fluorocytosine. As the name of the enzyme implies, it selectively removes amine groups from cytosine molecules and converts the relatively non-toxic 5-Fluorocytosine into 5-Fluorouracil, currently an effective anticancer compound in clinical use. By injecting the prodrug form and converting it to the active form only within the tumor (as a result of the TAPET technology), it is anticipated that unwanted side effects will be avoided and that the therapeutic response would be more potent. We feel that this program is likely to be a rich source of corporate collaborations in the future with potential milestones and royalty streams. This is from the dated full research report at the bottom of the list here: smallcapsonline.com Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next